US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nasus Pharma Ltd.

3.53

-0.1030-2.84%

Volume:926

Turnover:3.27K

Market Cap:41.47M

PE:-3.30

High:3.53

Open:3.53

Low:3.53

Close:3.63

52wk High:9.50

52wk Low:1.98

Shares:11.76M

Float Shares:6.21M

Volume Ratio:1.43

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.0691

EPS(LYR):-0.7311

ROE:-316.04%

ROA:-96.73%

PB:3.77

PE(LYR):-4.82

Loading ...

Overview Company News Filings

Amex Halt Add Info Lst 3.500000

THOMSON REUTERS

Nasus Pharma Names Interim CFO as Longtime Finance Chief Resigns

Nasus Pharma CFO Eyal Rubin to Exit; Finance Director Oren Elmaliach Named Interim CFO

Nasus Pharma - Oren Elmaliach Appointed Interim Chief Financial Officer at Nasus Pharma

THOMSON REUTERS

Press Release: Nasus Pharma Announces Transition of Chief Financial Officer

Nasus Pharma Boosts Cash and Equity in First-Half 2026 Filing

Nasus Pharma H1 EPS $(0.54) Misses $(0.20) Estimate

Benzinga Earnings

Nasus Pharma H1 FY26 Net Loss Widens to $5.94 Million

Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update

THOMSON REUTERS

Nasus Pharma CEO and Director Brendan O’Grady Files Initial Beneficial Ownership Statement

Nasus Pharma - Brendan P. O'grady Succeeds Dan Teleman as CEO Effective July 27, 2026

THOMSON REUTERS

Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'grady as Chief Executive Officer to Lead Strategic Growth

THOMSON REUTERS

Press Release: Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth

Nasus Pharma to present at Zacks Life Sciences Investor Forum

Nasus Pharma CEO Dan Benjamin Teleman acquires 6,550 shares for $20,305

Nasus Pharma plans first-in-human PK trial of intranasal ondansetron in Q3 2026

Nasus Pharma - to Initiate First-in-Human Pk Study of Ns003 in Q3 2026

THOMSON REUTERS

Nasus Pharma Announces Positive Results From Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (Ns003)

THOMSON REUTERS

Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)

Nasus Pharma hosts virtual KOL event on NS002 intranasal epinephrine for anaphylaxis

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/NSRX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NSRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","market":"US","secType":"STK","nameCN":"Nasus Pharma Ltd.","latestPrice":3.527,"timestamp":1791553337338,"preClose":3.63,"halted":0,"volume":926,"delay":0,"changeRate":-0.028374655647382854,"floatShares":6214000,"shares":11758900,"eps":-1.06915,"marketStatus":"Trading","change":-0.103,"latestTime":"10-09 09:45:10 EDT","open":3.527,"high":3.527,"low":3.527,"amount":3266.002,"amplitude":0,"askPrice":3.83,"askSize":100,"bidPrice":3.36,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.06915,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":2,"adr":0,"listingDate":1755057600000,"exchange":"AMEX","adjPreClose":3.63,"preHourTrading":{"tag":"盘前","latestPrice":3.68,"preClose":3.63,"latestTime":"09:08 EDT","volume":73,"amount":268.5863085,"timestamp":1791551281371,"change":0.05,"changeRate":0.013774,"amplitude":0.004931},"postHourTrading":{"tag":"盘后","latestPrice":3.63,"preClose":3.63,"latestTime":"19:30 EDT","volume":9,"amount":32.67,"timestamp":1791502204026,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.426592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","floatShares":6214000,"roa":"-96.73%","roe":"-316.04%","lyrEps":-0.731074,"volumeRatio":1.426592,"shares":11758900,"dividePrice":0,"high":3.527,"amplitude":0,"preClose":3.63,"low":3.527,"week52Low":1.98,"pbRate":"3.77","week52High":9.5,"institutionHeld":0,"latestPrice":3.527,"eps":-1.06915,"divideRate":0,"volume":926,"delay":0,"ttmEps":-1.06915,"open":3.527,"prevYearClose":9.15,"prevWeekClose":3.92,"prevMonthClose":3.69,"prevQuarterClose":3.69,"fiveDayClose":3.92,"twentyDayClose":3.4049,"sixtyDayClose":3.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NSRX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NSRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NSRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1766116800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NSRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NSRX","date":"2026-10-08","current":-3.298882,"percent":0.927083,"low":-51.389177,"twenty":-44.35909,"median":-25.76289,"eighty":-5.49944,"high":-3.720961,"avg":-23.270564,"sd":17.823117,"marketCap":44219625},"quantilePoints":[{"date":"2025-08-15","current":-47.343663,"twenty":-48.284655,"median":-47.931783,"eighty":-47.578911,"marketCap":72530491},{"date":"2025-08-22","current":-50.265593,"twenty":-50.691372,"median":-49.082873,"eighty":-48.024103,"marketCap":77006889},{"date":"2025-08-29","current":-47.604473,"twenty":-50.029049,"median":-48.047994,"eighty":-47.509856,"marketCap":72930053},{"date":"2025-09-05","current":-47.370886,"twenty":-49.082873,"median":-47.841017,"eighty":-47.486202,"marketCap":72572198},{"date":"2025-09-12","current":-48.136697,"twenty":-48.519903,"median":-47.66361,"eighty":-47.343663,"marketCap":73745420},{"date":"2025-09-19","current":-47.384488,"twenty":-48.195834,"median":-47.722745,"eighty":-47.36793,"marketCap":72593035},{"date":"2025-09-26","current":-47.604473,"twenty":-48.136697,"median":-47.604473,"eighty":-47.343663,"marketCap":72930053},{"date":"2025-10-03","current":-36.900859,"twenty":-48.077561,"median":-47.51577,"eighty":-47.308794,"marketCap":56532116},{"date":"2025-10-10","current":-45.830394,"twenty":-48.047993,"median":-47.384488,"eighty":-45.830394,"marketCap":70212163},{"date":"2025-10-17","current":-46.835706,"twenty":-47.900153,"median":-47.36793,"eighty":-45.534713,"marketCap":71752301},{"date":"2025-10-24","current":-44.943354,"twenty":-47.900153,"median":-47.314116,"eighty":-44.943354,"marketCap":68853218},{"date":"2025-10-31","current":-46.007802,"twenty":-47.900153,"median":-47.308794,"eighty":-45.239034,"marketCap":70483952},{"date":"2025-11-07","current":-44.647674,"twenty":-47.781881,"median":-47.308794,"eighty":-44.943354,"marketCap":68400236},{"date":"2025-11-14","current":-46.717433,"twenty":-47.722745,"median":-47.22009,"eighty":-44.647674,"marketCap":71571108},{"date":"2025-11-21","current":-41.395195,"twenty":-47.722745,"median":-46.835706,"eighty":-44.351994,"marketCap":63417438},{"date":"2025-11-28","current":-41.395195,"twenty":-47.675437,"median":-46.717433,"eighty":-43.654189,"marketCap":63417438},{"date":"2025-12-05","current":-40.508154,"twenty":-47.6163,"median":-46.155642,"eighty":-42.826285,"marketCap":62058492},{"date":"2025-12-12","current":-38.438395,"twenty":-47.604473,"median":-45.830394,"eighty":-41.395195,"marketCap":58887621},{"date":"2025-12-19","current":-37.669627,"twenty":-47.557164,"median":-45.682553,"eighty":-41.383368,"marketCap":57709868},{"date":"2025-12-26","current":-44.351994,"twenty":-47.509856,"median":-45.298465,"eighty":-41.395195,"marketCap":67947255},{"date":"2026-01-02","current":-43.332802,"twenty":-47.445516,"median":-44.987706,"eighty":-41.359713,"marketCap":82895651},{"date":"2026-01-09","current":-33.62436,"twenty":-47.384488,"median":-44.884218,"eighty":-40.236129,"marketCap":64323401},{"date":"2026-01-16","current":-33.62436,"twenty":-47.379047,"median":-44.647674,"eighty":-40.035066,"marketCap":64323401},{"date":"2026-01-23","current":-31.392839,"twenty":-47.370295,"median":-44.529402,"eighty":-38.570149,"marketCap":60054501},{"date":"2026-01-30","current":-26.473264,"twenty":-47.36793,"median":-44.351994,"eighty":-37.823381,"marketCap":50643354},{"date":"2026-02-06","current":-27.467787,"twenty":-47.363077,"median":-44.351994,"eighty":-35.774424,"marketCap":52545877},{"date":"2026-02-13","current":-34.411045,"twenty":-47.337754,"median":-43.81977,"eighty":-34.753161,"marketCap":65828330},{"date":"2026-02-20","current":-30.724148,"twenty":-47.314116,"median":-43.332802,"eighty":-34.411045,"marketCap":58775295},{"date":"2026-02-27","current":-31.33863,"twenty":-47.308794,"median":-42.873594,"eighty":-33.62436,"marketCap":59950800},{"date":"2026-03-06","current":-30.662699,"twenty":-47.308794,"median":-41.857638,"eighty":-33.151251,"marketCap":58657744},{"date":"2026-03-13","current":-28.389112,"twenty":-47.308794,"median":-41.483899,"eighty":-32.108896,"marketCap":54308372},{"date":"2026-03-20","current":-15.239177,"twenty":-47.308794,"median":-41.395195,"eighty":-31.096524,"marketCap":29152546},{"date":"2026-03-27","current":-4.817647,"twenty":-47.249657,"median":-41.365627,"eighty":-30.724148,"marketCap":28212141},{"date":"2026-04-02","current":-5.099481,"twenty":-47.249657,"median":-40.41945,"eighty":-29.587069,"marketCap":29862560},{"date":"2026-04-10","current":-4.639528,"twenty":-47.202349,"median":-40.212475,"eighty":-29.052754,"marketCap":27169074},{"date":"2026-04-17","current":-4.499542,"twenty":-47.048596,"median":-40.212475,"eighty":-28.102929,"marketCap":26349318},{"date":"2026-04-24","current":-6.799308,"twenty":-46.871188,"median":-39.325435,"eighty":-27.041563,"marketCap":39816747},{"date":"2026-05-01","current":-5.39945,"twenty":-46.741088,"median":-38.438986,"eighty":-25.76289,"marketCap":31619181},{"date":"2026-05-08","current":-6.77931,"twenty":-46.717433,"median":-38.438395,"eighty":-18.667992,"marketCap":39699639},{"date":"2026-05-15","current":-5.939395,"twenty":-46.670125,"median":-36.896469,"eighty":-15.349784,"marketCap":34781099},{"date":"2026-05-22","current":-5.739416,"twenty":-46.374445,"median":-36.254495,"eighty":-7.119275,"marketCap":33610018},{"date":"2026-05-29","current":-6.399349,"twenty":-46.126074,"median":-35.850198,"eighty":-6.399349,"marketCap":37474585},{"date":"2026-06-05","current":-6.47934,"twenty":-46.007802,"median":-35.518691,"eighty":-6.399349,"marketCap":37943017},{"date":"2026-06-12","current":-6.339355,"twenty":-45.901357,"median":-34.571052,"eighty":-6.29136,"marketCap":37123261},{"date":"2026-06-18","current":-6.159373,"twenty":-45.830394,"median":-34.411045,"eighty":-6.175371,"marketCap":36069288},{"date":"2026-06-26","current":-6.599328,"twenty":-45.830394,"median":-33.62436,"eighty":-6.175371,"marketCap":38645666},{"date":"2026-07-02","current":-7.029284,"twenty":-45.771258,"median":-33.505965,"eighty":-6.207368,"marketCap":41163490},{"date":"2026-07-10","current":-6.019387,"twenty":-45.49935,"median":-32.81339,"eighty":-6.167372,"marketCap":35249532},{"date":"2026-07-17","current":-6.139375,"twenty":-45.334124,"median":-32.21535,"eighty":-6.139375,"marketCap":35952180},{"date":"2026-07-24","current":-6.18537,"twenty":-45.191725,"median":-31.392839,"eighty":-6.099379,"marketCap":36221529},{"date":"2026-07-31","current":-6.359353,"twenty":-45.00249,"median":-31.096524,"eighty":-6.099379,"marketCap":37240369},{"date":"2026-08-07","current":-6.77931,"twenty":-44.972922,"median":-30.724148,"eighty":-6.099379,"marketCap":39699639},{"date":"2026-08-14","current":-6.399349,"twenty":-44.943354,"median":-30.662699,"eighty":-6.099379,"marketCap":37474585},{"date":"2026-08-21","current":-4.275233,"twenty":-44.884218,"median":-29.56931,"eighty":-6.079381,"marketCap":45086610},{"date":"2026-08-28","current":-4.552846,"twenty":-44.798471,"median":-29.220042,"eighty":-6.059383,"marketCap":48014312},{"date":"2026-09-04","current":-4.164188,"twenty":-44.647674,"median":-28.450561,"eighty":-6.019387,"marketCap":43915530},{"date":"2026-09-11","current":-3.720961,"twenty":-44.647674,"median":-28.266216,"eighty":-5.923397,"marketCap":39241256},{"date":"2026-09-18","current":-3.920893,"twenty":-44.647674,"median":-27.467787,"eighty":-5.819408,"marketCap":41349742},{"date":"2026-09-25","current":-3.865357,"twenty":-44.458439,"median":-26.828451,"eighty":-5.775412,"marketCap":40764051},{"date":"2026-10-02","current":-4.237453,"twenty":-44.378013,"median":-26.04704,"eighty":-5.707419,"marketCap":44688177},{"date":"2026-10-08","current":-4.193023,"twenty":-44.35909,"median":-25.76289,"eighty":-5.49944,"marketCap":44219625}],"updateTime":1791553510766},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NSRX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664868515","title":"Amex Halt Add Info Lst 3.500000","url":"https://stock-news.laohu8.com/highlight/detail?id=2664868515","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664868515?lang=en_us&edition=fundamental","pubTime":"2026-09-02 00:15","pubTimestamp":1788279309,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nAQN2MHJNP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660426740","title":"Nasus Pharma Names Interim CFO as Longtime Finance Chief Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2660426740","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660426740?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:47","pubTimestamp":1787147264,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd. ( ($NSRX) ) has provided an update. Nasus Pharma Ltd. reported on August 19, 2026, that Chief Financial Officer Eyal Rubin has re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-names-interim-cfo-as-longtime-finance-chief-resigns?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-names-interim-cfo-as-longtime-finance-chief-resigns?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660447838","title":"Nasus Pharma CFO Eyal Rubin to Exit; Finance Director Oren Elmaliach Named Interim CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2660447838","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660447838?lang=en_us&edition=fundamental","pubTime":"2026-08-19 19:00","pubTimestamp":1787137251,"startTime":"0","endTime":"0","summary":"Nasus Pharma CFO Eyal Rubin to exit; finance director Oren Elmaliach named interim CFONasus Pharma CFO Eyal Rubin will leave to pursue an opportunity outside the life sciences industry.Rubin will rema","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL9JvcQx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014039.USD","LU2210149790.SGD","IE00BQXX3D17.EUR","IE00BN0W2V16.EUR","IE00BQXX3F31.USD","BK4112","IE00B3QW5Z07.USD","BCDF","BK4007","IE00B64PRP62.GBP","SG9999014021.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","NDAQ","NSRX","IE00BN0W2T93.GBP","BK4588","BK4585","LU0314104364.USD","SG9999014013.SGD","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014005.SGD","IE00BQXX3C00.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660027442","title":"Nasus Pharma - Oren Elmaliach Appointed Interim Chief Financial Officer at Nasus Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2660027442","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660027442?lang=en_us&edition=fundamental","pubTime":"2026-08-19 19:00","pubTimestamp":1787137202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nTUA4PKWBX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660004442","title":"Press Release: Nasus Pharma Announces Transition of Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660004442","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660004442?lang=en_us&edition=fundamental","pubTime":"2026-08-19 19:00","pubTimestamp":1787137200,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) (\"Nasus\", \"Nasus Pharma\" or the \"Company\"), a clinical-stage pharmaceutical company focused on the developme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660389954","title":"Nasus Pharma Boosts Cash and Equity in First-Half 2026 Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2660389954","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660389954?lang=en_us&edition=fundamental","pubTime":"2026-08-17 21:22","pubTimestamp":1786972943,"startTime":"0","endTime":"0","summary":"An update from Nasus Pharma Ltd. ( ($NSRX) ) is now available. Nasus Pharma filed a Form 6-K in August 2026, providing unaudited condensed consolid...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-boosts-cash-and-equity-in-first-half-2026-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-boosts-cash-and-equity-in-first-half-2026-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4585","EQR","VMRK","BK4215","NSRX","BK4588","REZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660875094","title":"Nasus Pharma H1 EPS $(0.54) Misses $(0.20) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2660875094","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660875094?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:15","pubTimestamp":1786968947,"startTime":"0","endTime":"0","summary":"Nasus Pharma (AMEX:NSRX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.20) by 170 percent. This is a 217.65 percent decrease over losses of $(0.17) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61243652/nasus-pharma-h1-eps-0-54-misses-0-20-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660487516","title":"Nasus Pharma H1 FY26 Net Loss Widens to $5.94 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660487516","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660487516?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:14","pubTimestamp":1786968889,"startTime":"0","endTime":"0","summary":"Nasus Pharma H1 FY26 net loss widens to $5.94 millionNasus Pharma posted a net loss of USD 5.9 million for the six months ended June 30, 2026, widening from USD 1.3 million.R&D expense rose to USD 2.6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL8nPTMZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","BCDF","IE00BGHQF748.EUR","NDAQ","IE00BN0W2W23.USD","NSRX","BK4588","LU0314104364.USD","BK4585","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014039.USD","BK4007","BK4112","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660848759","title":"Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848759","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660848759?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:14","pubTimestamp":1786968869,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUA3XWYVH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656399299","title":"Nasus Pharma CEO and Director Brendan O’Grady Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2656399299","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656399299?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:26","pubTimestamp":1785529572,"startTime":"0","endTime":"0","summary":"Nasus Pharma CEO and Director Brendan O’Grady files initial beneficial ownership statementNasus Pharma filed an SEC Form 3 for Brendan P. O’Grady, naming him chief executive officer, director.Disclaim","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL21WDjh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654009414","title":"Nasus Pharma - Brendan P. O'grady Succeeds Dan Teleman as CEO Effective July 27, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2654009414","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654009414?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:30","pubTimestamp":1785238200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nTUA9RLTTX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654009106","title":"Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'grady as Chief Executive Officer to Lead Strategic Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2654009106","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654009106?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:30","pubTimestamp":1785238200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nTUA9RLTTX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654009230","title":"Press Release: Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2654009230","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654009230?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:30","pubTimestamp":1785238200,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (\"Nasus\", \"Nasus Pharma\" or the \"Company\"), a clinical-stage pharmaceutical company focused on the development of inn","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4232","DBB","BK4022","R","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645241870","title":"Nasus Pharma to present at Zacks Life Sciences Investor Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2645241870","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645241870?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:03","pubTimestamp":1782129826,"startTime":"0","endTime":"0","summary":"Nasus Pharma will present at the Zacks Life Sciences Investor Forum on June 24, 2026, 11:00-11:30 a.m. ET.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL9y3wgP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","SG9999014021.USD","LU2095319765.USD","BK4588","LU2210150020.SGD","LU0314104364.USD","BK4007","NSRX","IE00BN0W2T93.GBP","SG9999014005.SGD","BK4585","BK4112","IE00B64PRP62.GBP","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014039.USD","SG9999014013.SGD","IE00BGHQF748.EUR","NDAQ","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645702186","title":"Nasus Pharma CEO Dan Benjamin Teleman acquires 6,550 shares for $20,305","url":"https://stock-news.laohu8.com/highlight/detail?id=2645702186","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645702186?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:13","pubTimestamp":1782126798,"startTime":"0","endTime":"0","summary":"Nasus Pharma CEO Dan Benjamin Teleman bought 6,550 ordinary shares at USD 3.1 each, a Form 4 filing shows.Teleman reported 163,541 ordinary shares beneficially owned following the purchase.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL98bHMv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Nasus Pharma CEO Dan Benjamin Teleman acquires 6,550 shares for $20,305","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642467364","title":"Nasus Pharma plans first-in-human PK trial of intranasal ondansetron in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642467364","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642467364?lang=en_us&edition=fundamental","pubTime":"2026-06-09 20:02","pubTimestamp":1781006538,"startTime":"0","endTime":"0","summary":"Nasus Pharma reported positive preclinical pharmacokinetic and safety results for NS003, its intranasal ondansetron powder for nausea and vomiting.Results have already been presented, supporting a comparable drug exposure profile to intravenous ondansetron in an animal study.A separate toxicology study showed a favorable safety profile, with no adverse effects observed at higher dosing.The program is slated to move into a first-in-human pharmacokinetic study in the third quarter of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL5T03MZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","BK4007","IE00BN0W2T93.GBP","SG9999014021.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2095319765.USD","NDAQ","LU0314104364.USD","BK4112","BK4585","NSRX","IE00BKPKM429.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014039.USD","IE00B64PRP62.GBP","SG9999014005.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642675574","title":"Nasus Pharma - to Initiate First-in-Human Pk Study of Ns003 in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642675574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642675574?lang=en_us&edition=fundamental","pubTime":"2026-06-09 20:00","pubTimestamp":1781006404,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nTUA20QPYC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642048462","title":"Nasus Pharma Announces Positive Results From Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (Ns003)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642048462","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642048462?lang=en_us&edition=fundamental","pubTime":"2026-06-09 20:00","pubTimestamp":1781006404,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nTUA20QPYC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642467609","title":"Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642467609","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642467609?lang=en_us&edition=fundamental","pubTime":"2026-06-09 20:00","pubTimestamp":1781006400,"startTime":"0","endTime":"0","summary":"Study Comparing Intranasal Powder Formulation of Ondansetron Demonstrates Comparable Pharmacokinetic Profile to Intravenous Ondansetron in Animal Study;Program to Advance to First-in-Human PK Study in","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/09/3308784/0/en/Nasus-Pharma-Announces-Positive-Results-from-Preclinical-Pharmacokinetic-and-Safety-Study-of-Intranasal-Ondansetron-NS003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUC","BK4588","BK4520","BK4516","NSRX","BK4006","X","BK4585","BK4123","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640895949","title":"Nasus Pharma hosts virtual KOL event on NS002 intranasal epinephrine for anaphylaxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2640895949","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640895949?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:00","pubTimestamp":1780315248,"startTime":"0","endTime":"0","summary":"Nasus Pharma will host a virtual KOL event on June 10, 2026 at 8:00 AM ET focused on anaphylaxis treatment.Management plans to highlight NS002, an intranasal epinephrine powder candidate, with discussion of Phase 2 results versus EpiPen injection.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL6nncK1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","SG9999014021.USD","LU2095319765.USD","BK4588","LU2210150020.SGD","LU0314104364.USD","BK4007","NSRX","IE00BN0W2T93.GBP","SG9999014005.SGD","BK4585","BK4112","IE00B64PRP62.GBP","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014039.USD","SG9999014013.SGD","IE00BGHQF748.EUR","NDAQ","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":42,"code":"91000000","status":"200"}]}}